Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE3
Total Enrollment
58 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-05-10
Study Completion Date
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Bipolar disorder (BD) is a frequent and lifelong recurrent mood disorder with treatment-resistant depressive episodes. Importantly, depressive symptoms and cognitive decline are major determinants of functionality and quality of life in this clinical population. There is robust evidence that individuals with BD have neurocognitive deficits (especially in memory and executive functioning domains) compared to the healthy population. These deficits are present in all mood states and can greatly affect patients' functional capacity, often more so than mood symptoms themselves. Many pharmacological treatments for BD adversely affect cognition, and those that are beneficial can be difficult to use. There is thus a pressing need to identify a safe, easy-to-use medication that can target both cognitive deficits and depressive symptoms in BD. It is expected that Brexpiprazole adjunctive treatment will be efficacious in treating BD type I and type II depression by improving mood symptoms, as well as cognitive capacity and global functioning, and that such changes will be accompanied by concurrent alterations in associated brain structures.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
NCT03287869
Bipolar I Disorder
Acute Mania
COMPLETED
PHASE3
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
NCT03257865
Bipolar I Disorder
Manic Episode
COMPLETED
PHASE3
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
NCT03259555
Bipolar I Disorder
Manic Episode
COMPLETED
PHASE3
Brexpiprazole for Bipolar Depression
NCT03427892
Bipolar Depression
COMPLETED
PHASE4
Imaging 5HT7 Antagonist Effects in Bipolar Disorder
NCT03633357
Bipolar Disorder
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The estimated lifetime prevalence of bipolar disorders is 0.55% for bipolar type I and 1.65% for bipolar type II. In the long term, patients with a bipolar disorder spend on average 60% of their time in depressive states, with intermittent hypomanic or manic phases. Moreover, the depressive episodes tend to become more frequent and difficult to treat as they grow in number and/or frequency. Many studies have demonstrated that even so-called stabilized bipolar patients will go through frequent subsyndromal depressive symptoms during a significant portion of any given year.
Bipolar depression is heavily loaded with general symptoms of psychomotor retardation, anergia, hypersomnolence, hyperphagia, decreased motivation, anhedonia and cognitive difficulties. All these functions are modulated by dopamine, and strategies aimed at improving dopaminergic function are frequently used to resolve residual symptoms of bipolar depression. Brexpiprazole is a new serotonin-dopamine antagonist which possesses unique capabilities with partial dopaminergic (D2) agonistic activities. Moreover, like other atypical agents, Brexpiprazole is a potent antagonist of the 5-HT2a receptor, as well as the adrenergic α1b and α2c receptors, and is a 5-HT1a post-synaptic agonist. These properties enable the molecule to provide antidepressant potentiating capabilities. While Brexpiprazole is currently recognized for its capacity to potentiate antidepressant effects in unipolar depression, there is still a need to evaluate the molecule's effect in bipolar depression.
Depressive symptoms and cognitive deficits are major determinants of functionality and quality of life in individuals with bipolar disorders. Cognitive problems tend to increase with the number of mood episodes, psychotic symptoms, and anxiety. Further, certain medications (and especially polypharmacy) can increase cognitive decline in the long term. As the average age of the patient population increases, risk for cognitive decline due to aging and prolonged medication use is of importance. From a neuroanatomical perspective, current neuroscience literature has related treatment with Aripiprazole to improved memory performance and structural changes in the hippocampus in patients at an early stage of psychosis. The chemically and pharmacologically related compound Brexpiprazole is thus a promising candidate for targeting both depressive symptoms and cognitive deficits observed in bipolar depression given its partial agonistic activity at the D2 receptor and, possibly, because of its 5-HT7 antagonistic activity.
Treatment of bipolar depression is further complicated by the knowledge that, in the long-term, use of antidepressants may be associated with manic/hypomanic switches, rapid cycling, and mixed features. These further increase the risk of cognitive decline and suicidality. In fact, the suicide rate in bipolar disorders is relatively high compared with other disorders, with certain studies reporting that up to 50% of bipolar patients will attempt suicide. Further, mortality is considerably higher among patients with bipolar disorders as compared to the general population given patients' high risk for diabetes and cardiovascular disorders (considerably increased by valproate and antipsychotic treatment). In the prevention of excess mortality, selection of first-line medications with a smaller effect on weight is essential.
Further, an interesting new phenotype for the personalized treatment of bipolar disorders is dysregulated biological rhythms (i.e., sleeping and eating patterns). This is a core etiopathological feature of bipolar disorders, and has been associated with obesity, cancer, and accelerated mortality in the general population. It has been previously shown that a majority of patients with bipolar disorders show a specific pattern of disorganized activity rhythm that is associated with treatment resistance, mood lability and obesity. It was recently reported that Aripiprazole can correct this type of disorganized rhythm. Based on an animal model, this effect is linked to dopaminergic activity. It is expected that Brexpiprazole will have a similar effect. This is supported by a recent sleep study of Brexpiprazole in treatment-resistant major depressive disorder that found an improvement of most sleep parameters in addition to decreasing daytime sleepiness and improving mood symptoms.
In addition, insulin resistance is shown to be one of the most robust predictors of a more chronic course of bipolar disorder. C-reactive protein (CRP) was shown to be two times greater in patients with insulin resistance compared to those without. Higher CRP is thus considered to be a predictor of treatment-resistance and cardiovascular risk in this clinical population. Most importantly, treatment response has been associated with decreasing CRP, decreasing insulin resistance, and decreasing depressive symptoms. As such, treatment-resistant bipolar depression can be viewed as a metabolic mood syndrome that is associated with a cognitive decline.
Taken together, there is a need to improve the repertoire of treatments for bipolar depression. One would favor strategies that procure a rapid onset of action as well as a low risk of switching to hypomania and weight gain. Finally, one would favor strategies that would procure relief for the most frequent and persistent symptoms of bipolar depression, such as psychomotor retardation, cognitive deficits, and reversed neurovegetative symptoms. Thus, the current study will evaluate the efficacy and tolerability of an adjunctive, variable dose of Brexpiprazole treatment in bipolar depression.
Bipolar depression is heavily loaded with general symptoms of psychomotor retardation, anergia, hypersomnolence, hyperphagia, decreased motivation, anhedonia and cognitive difficulties. All these functions are modulated by dopamine, and strategies aimed at improving dopaminergic function are frequently used to resolve residual symptoms of bipolar depression. Brexpiprazole is a new serotonin-dopamine antagonist which possesses unique capabilities with partial dopaminergic (D2) agonistic activities. Moreover, like other atypical agents, Brexpiprazole is a potent antagonist of the 5-HT2a receptor, as well as the adrenergic α1b and α2c receptors, and is a 5-HT1a post-synaptic agonist. These properties enable the molecule to provide antidepressant potentiating capabilities. While Brexpiprazole is currently recognized for its capacity to potentiate antidepressant effects in unipolar depression, there is still a need to evaluate the molecule's effect in bipolar depression.
Depressive symptoms and cognitive deficits are major determinants of functionality and quality of life in individuals with bipolar disorders. Cognitive problems tend to increase with the number of mood episodes, psychotic symptoms, and anxiety. Further, certain medications (and especially polypharmacy) can increase cognitive decline in the long term. As the average age of the patient population increases, risk for cognitive decline due to aging and prolonged medication use is of importance. From a neuroanatomical perspective, current neuroscience literature has related treatment with Aripiprazole to improved memory performance and structural changes in the hippocampus in patients at an early stage of psychosis. The chemically and pharmacologically related compound Brexpiprazole is thus a promising candidate for targeting both depressive symptoms and cognitive deficits observed in bipolar depression given its partial agonistic activity at the D2 receptor and, possibly, because of its 5-HT7 antagonistic activity.
Treatment of bipolar depression is further complicated by the knowledge that, in the long-term, use of antidepressants may be associated with manic/hypomanic switches, rapid cycling, and mixed features. These further increase the risk of cognitive decline and suicidality. In fact, the suicide rate in bipolar disorders is relatively high compared with other disorders, with certain studies reporting that up to 50% of bipolar patients will attempt suicide. Further, mortality is considerably higher among patients with bipolar disorders as compared to the general population given patients' high risk for diabetes and cardiovascular disorders (considerably increased by valproate and antipsychotic treatment). In the prevention of excess mortality, selection of first-line medications with a smaller effect on weight is essential.
Further, an interesting new phenotype for the personalized treatment of bipolar disorders is dysregulated biological rhythms (i.e., sleeping and eating patterns). This is a core etiopathological feature of bipolar disorders, and has been associated with obesity, cancer, and accelerated mortality in the general population. It has been previously shown that a majority of patients with bipolar disorders show a specific pattern of disorganized activity rhythm that is associated with treatment resistance, mood lability and obesity. It was recently reported that Aripiprazole can correct this type of disorganized rhythm. Based on an animal model, this effect is linked to dopaminergic activity. It is expected that Brexpiprazole will have a similar effect. This is supported by a recent sleep study of Brexpiprazole in treatment-resistant major depressive disorder that found an improvement of most sleep parameters in addition to decreasing daytime sleepiness and improving mood symptoms.
In addition, insulin resistance is shown to be one of the most robust predictors of a more chronic course of bipolar disorder. C-reactive protein (CRP) was shown to be two times greater in patients with insulin resistance compared to those without. Higher CRP is thus considered to be a predictor of treatment-resistance and cardiovascular risk in this clinical population. Most importantly, treatment response has been associated with decreasing CRP, decreasing insulin resistance, and decreasing depressive symptoms. As such, treatment-resistant bipolar depression can be viewed as a metabolic mood syndrome that is associated with a cognitive decline.
Taken together, there is a need to improve the repertoire of treatments for bipolar depression. One would favor strategies that procure a rapid onset of action as well as a low risk of switching to hypomania and weight gain. Finally, one would favor strategies that would procure relief for the most frequent and persistent symptoms of bipolar depression, such as psychomotor retardation, cognitive deficits, and reversed neurovegetative symptoms. Thus, the current study will evaluate the efficacy and tolerability of an adjunctive, variable dose of Brexpiprazole treatment in bipolar depression.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Bipolar Depression
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient
Individuals diagnosed with Bipolar Disorder Type I or Type II and suffering a major depressive episode who will receive an adjunctive and variable dose of Brexpiprazole treatment
Group Type
EXPERIMENTAL
Brexpiprazole
Intervention Type
DRUG
Adjunctive variable dose (1-3 mg/day) Brexpiprazole
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brexpiprazole
Adjunctive variable dose (1-3 mg/day) Brexpiprazole
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 18-75
* Male or female
* Bipolar Disorder type I or type II
* Current treatment-resistant depressive episode (with MADRS \>/= 24 and item 2 (reported sadness) \>/= 3) for a minimum of 2 weeks but \</= 52 weeks at screening visit and baseline visit
* Patients must have failed at least one other treatment for the current depressive episode
* If female and of childbearing potential, is using an adequate method of contraception. Adequate methods of contraception include abstinence; oral contraceptive pill or surgically implanted device; intra-uterine device; condom plus spermicidal foam or jelly; or tubal ligation
* Is treated with a mood stabilizer (lithium and/or valproate and/or lamotrigine and/or quetiapine \</= 100mg/day)
* The following laboratory values are within normal limits at Screening: CBC with differential; ferritin; extended electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate); thyroid function test(s); kidney function tests; hemoglobin A1c; lipid profile; prolactin
* Normal EKG at Screening
* Patient is able to give his(her) consent
* Age: 18-75
* Male or female
* No current or past history of any psychiatric disorder
* Patients must have failed at least one other treatment for the current depressive episode
* If female and of childbearing potential, is using an adequate method of contraception. Adequate methods of contraception include abstinence; oral contraceptive pill or surgically implanted device; intra-uterine device; condom plus spermicidal foam or jelly; or tubal ligation
* The following laboratory values are within normal limits at Screening: CBC with differential; ferritin; extended electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate); thyroid function test(s); kidney function tests; hemoglobin A1c; lipid profile; prolactin
* Normal EKG at Screening
* Patient is able to give his(her) consent
* Male or female
* Bipolar Disorder type I or type II
* Current treatment-resistant depressive episode (with MADRS \>/= 24 and item 2 (reported sadness) \>/= 3) for a minimum of 2 weeks but \</= 52 weeks at screening visit and baseline visit
* Patients must have failed at least one other treatment for the current depressive episode
* If female and of childbearing potential, is using an adequate method of contraception. Adequate methods of contraception include abstinence; oral contraceptive pill or surgically implanted device; intra-uterine device; condom plus spermicidal foam or jelly; or tubal ligation
* Is treated with a mood stabilizer (lithium and/or valproate and/or lamotrigine and/or quetiapine \</= 100mg/day)
* The following laboratory values are within normal limits at Screening: CBC with differential; ferritin; extended electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate); thyroid function test(s); kidney function tests; hemoglobin A1c; lipid profile; prolactin
* Normal EKG at Screening
* Patient is able to give his(her) consent
* Age: 18-75
* Male or female
* No current or past history of any psychiatric disorder
* Patients must have failed at least one other treatment for the current depressive episode
* If female and of childbearing potential, is using an adequate method of contraception. Adequate methods of contraception include abstinence; oral contraceptive pill or surgically implanted device; intra-uterine device; condom plus spermicidal foam or jelly; or tubal ligation
* The following laboratory values are within normal limits at Screening: CBC with differential; ferritin; extended electrolytes (sodium, potassium, chloride, calcium, magnesium, phosphate); thyroid function test(s); kidney function tests; hemoglobin A1c; lipid profile; prolactin
* Normal EKG at Screening
* Patient is able to give his(her) consent
Exclusion Criteria
* Is at high risk of suicide as defined by a score of \>/= 3 to item 10 of MADRS and/or in the clinical opinion of the investigator
* Hypo(mania) episode with YMRS \>/= 8
* Psychotic symptoms as defined by a score of \>/= 4 to item 8 (content) of YMRS and/or in the opinion of the investigator
* Is treated with fluoxetine OR carbamazepine
* Is treated with risperidone OR olanzapine OR quetiapine \> 100mg/day OR ziprazidone OR any other antipsychotic
* Is pregnant or lactating or absence of contraceptive treatment
* Drug abuse or dependence as per DSM-V (MINI)
* Unstable medical condition
* Other unstable and/or untreated psychiatric condition, organic brain disorder, unstable and/or untreated medical condition such as hypothyroidism, hyperthyroidism, diabetes, cardiac condition, hypertension
* Deficit in vitamin B12 or folate
* Rapid cycling (more than 4 mood episodes per year)
* Active or history of difficulty to swallow
* Seizures not currently controlled with medications
* Orthostatic hypotension defined as a drop in systolic blood pressure of at least 20 mmHg or of diastolic BP of at least 10 mmHg within 3 minutes of standing
* A history of clinically significant cardiovascular disorders and cardiac arrhythmias
* A low white blood cell count
* Known eye disease
* Involuntary, irregular muscle movements, especially in the face
* Known hypersensitivity to Brexpiprazole and any components of its formulation
* Known lactose intolerance or have hereditary galactose intolerance or glucose-galactose malabsorption, because Brexpiprazole and placebo tablets contain lactose (a disaccharide of glucose and galactose)
* Active inflammatory disease including lupus, colitis, Crohn's disease, psoriasis, irritable bowel syndrome (IBS)
* Mild or major neurocognitive disorder
* Previous history of sensitivity/low tolerance to medications metabolized by CYP 2D6 inhibitors, or CYP 3A4 inducers
* Alcohol or drug abuse
* Deficit in vitamin B12 or folate
* Seizures not currently controlled with medications
* History of clinically significant cardiovascular disorders and cardiac arrhythmias
* Mild or major neurocognitive disorder
* Pacemaker
* Heart/vascular clip
* Metal prosthesis
* Metal fragments in body
* Transdermal patch
* Aneurysm clip
* Prosthetic valve
* Claustrophobia
* Pregnant
* Hypo(mania) episode with YMRS \>/= 8
* Psychotic symptoms as defined by a score of \>/= 4 to item 8 (content) of YMRS and/or in the opinion of the investigator
* Is treated with fluoxetine OR carbamazepine
* Is treated with risperidone OR olanzapine OR quetiapine \> 100mg/day OR ziprazidone OR any other antipsychotic
* Is pregnant or lactating or absence of contraceptive treatment
* Drug abuse or dependence as per DSM-V (MINI)
* Unstable medical condition
* Other unstable and/or untreated psychiatric condition, organic brain disorder, unstable and/or untreated medical condition such as hypothyroidism, hyperthyroidism, diabetes, cardiac condition, hypertension
* Deficit in vitamin B12 or folate
* Rapid cycling (more than 4 mood episodes per year)
* Active or history of difficulty to swallow
* Seizures not currently controlled with medications
* Orthostatic hypotension defined as a drop in systolic blood pressure of at least 20 mmHg or of diastolic BP of at least 10 mmHg within 3 minutes of standing
* A history of clinically significant cardiovascular disorders and cardiac arrhythmias
* A low white blood cell count
* Known eye disease
* Involuntary, irregular muscle movements, especially in the face
* Known hypersensitivity to Brexpiprazole and any components of its formulation
* Known lactose intolerance or have hereditary galactose intolerance or glucose-galactose malabsorption, because Brexpiprazole and placebo tablets contain lactose (a disaccharide of glucose and galactose)
* Active inflammatory disease including lupus, colitis, Crohn's disease, psoriasis, irritable bowel syndrome (IBS)
* Mild or major neurocognitive disorder
* Previous history of sensitivity/low tolerance to medications metabolized by CYP 2D6 inhibitors, or CYP 3A4 inducers
* Alcohol or drug abuse
* Deficit in vitamin B12 or folate
* Seizures not currently controlled with medications
* History of clinically significant cardiovascular disorders and cardiac arrhythmias
* Mild or major neurocognitive disorder
* Pacemaker
* Heart/vascular clip
* Metal prosthesis
* Metal fragments in body
* Transdermal patch
* Aneurysm clip
* Prosthetic valve
* Claustrophobia
* Pregnant
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
McMaster University
OTHER
Sponsor Role
collaborator
Jewish General Hospital
OTHER
Sponsor Role
collaborator
Douglas Mental Health University Institute
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Serge Beaulieu
MD, PhD, FRCPC, DFAPA, Medical Chief
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Serge Beaulieu, MD, PhD, FRCPC, DFAPA
Role: PRINCIPAL_INVESTIGATOR
Douglas Mental Health University Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
McMaster University
Hamilton, Ontario, Canada
Site Status
TERMINATED
Jewish General Hospital
Montreal, Quebec, Canada
Site Status
WITHDRAWN
Douglas Mental Health University Institute
Montreal, Quebec, Canada
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
MD, MSc
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998 Sep;50(2-3):143-51. doi: 10.1016/s0165-0327(98)00142-6.
Reference Type
BACKGROUND
Parker G. How should mood disorders be modelled? Aust N Z J Psychiatry. 2008 Oct;42(10):841-50. doi: 10.1080/00048670802345458.
Reference Type
BACKGROUND
Pallaskorpi S, Suominen K, Ketokivi M, Mantere O, Arvilommi P, Valtonen H, Leppamaki S, Isometsa E. Five-year outcome of bipolar I and II disorders: findings of the Jorvi Bipolar Study. Bipolar Disord. 2015 Jun;17(4):363-74. doi: 10.1111/bdi.12291. Epub 2015 Mar 2.
Reference Type
BACKGROUND
Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002 Jun;59(6):530-7. doi: 10.1001/archpsyc.59.6.530.
Reference Type
BACKGROUND
Andreou C, Bozikas VP. The predictive significance of neurocognitive factors for functional outcome in bipolar disorder. Curr Opin Psychiatry. 2013 Jan;26(1):54-9. doi: 10.1097/YCO.0b013e32835a2acf.
Reference Type
BACKGROUND
Miskowiak KW, Burdick KE, Martinez-Aran A, Bonnin CM, Bowie CR, Carvalho AF, Gallagher P, Lafer B, Lopez-Jaramillo C, Sumiyoshi T, McIntyre RS, Schaffer A, Porter RJ, Purdon S, Torres IJ, Yatham LN, Young AH, Kessing LV, Vieta E. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. Bipolar Disord. 2018 May;20(3):184-194. doi: 10.1111/bdi.12595. Epub 2018 Jan 18.
Reference Type
BACKGROUND
Pallaskorpi S, Suominen K, Ketokivi M, Valtonen H, Arvilommi P, Mantere O, Leppamaki S, Isometsa E. Incidence and predictors of suicide attempts in bipolar I and II disorders: A 5-year follow-up study. Bipolar Disord. 2017 Feb;19(1):13-22. doi: 10.1111/bdi.12464. Epub 2017 Feb 8.
Reference Type
BACKGROUND
Hoang U, Goldacre MJ, Stewart R. Avoidable mortality in people with schizophrenia or bipolar disorder in England. Acta Psychiatr Scand. 2013 Mar;127(3):195-201. doi: 10.1111/acps.12045. Epub 2012 Dec 9.
Reference Type
BACKGROUND
Melo MC, Garcia RF, Linhares Neto VB, Sa MB, de Mesquita LM, de Araujo CF, de Bruin VM. Sleep and circadian alterations in people at risk for bipolar disorder: A systematic review. J Psychiatr Res. 2016 Dec;83:211-219. doi: 10.1016/j.jpsychires.2016.09.005. Epub 2016 Sep 13.
Reference Type
BACKGROUND
Hsu WY, Lane HY, Lin CH. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease. Front Psychiatry. 2018 Apr 4;9:91. doi: 10.3389/fpsyt.2018.00091. eCollection 2018.
Reference Type
BACKGROUND
Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004 Mar;161(3):564-6. doi: 10.1176/appi.ajp.161.3.564.
Reference Type
BACKGROUND
Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004 Jul 1;56(1):54-60. doi: 10.1016/j.biopsych.2004.03.013.
Reference Type
BACKGROUND
El-Mallakh RS, Penagaluri P, Kantamneni A, Gao Y, Roberts RJ. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q. 2010 Sep;81(3):207-13. doi: 10.1007/s11126-010-9130-6.
Reference Type
BACKGROUND
Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015 Sep;69(9):978-97. doi: 10.1111/ijcp.12714. Epub 2015 Aug 6.
Reference Type
BACKGROUND
Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015 Sep;76(9):1224-31. doi: 10.4088/JCP.14m09688.
Reference Type
BACKGROUND
Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015 Sep;76(9):1232-40. doi: 10.4088/JCP.14m09689.
Reference Type
BACKGROUND
Martinez-Aran A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J, Benabarre A, Goikolea JM, Comes M, Salamero M. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry. 2004 Feb;161(2):262-70. doi: 10.1176/appi.ajp.161.2.262.
Reference Type
BACKGROUND
Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl. 2007;(434):17-26. doi: 10.1111/j.1600-0447.2007.01055.x.
Reference Type
BACKGROUND
Weisler RH, Ota A, Tsuneyoshi K, Perry P, Weiller E, Baker RA, Sheehan DV. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. J Affect Disord. 2016 Nov 1;204:40-7. doi: 10.1016/j.jad.2016.06.001. Epub 2016 Jun 4.
Reference Type
BACKGROUND
Buyukkurt A, Bourguignon C, Antinora C, Farquhar E, Gao X, Passarella E, Sibthorpe D, Gou K, Saury S, Beaulieu S, Storch KF, Linnaranta O. Irregular eating patterns associate with hypomanic symptoms in bipolar disorders. Nutr Neurosci. 2021 Jan;24(1):23-34. doi: 10.1080/1028415X.2019.1587136. Epub 2019 Mar 15.
Reference Type
BACKGROUND
Takaki M. Aripiprazole as monotherapy at bedtime was effective for treatment of two cases of obsessive-compulsive disorder and insomnia. J Neuropsychiatry Clin Neurosci. 2014 Summer;26(3):E64. doi: 10.1176/appi.neuropsych.13100245. No abstract available.
Reference Type
BACKGROUND
Tashiro T. Improvement of a patient's circadian rhythm sleep disorders by aripiprazole was associated with stabilization of his bipolar illness. J Sleep Res. 2017 Apr;26(2):247-250. doi: 10.1111/jsr.12496. Epub 2017 Jan 24.
Reference Type
BACKGROUND
Blum K, Febo M, Badgaiyan RD, Braverman ER, Dushaj K, Li M, Demetrovics Z. Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Curr Pharm Des. 2016;22(38):5837-5854. doi: 10.2174/1381612822666160719111346.
Reference Type
BACKGROUND
Krystal AD, Mittoux A, Meisels P, Baker RA. Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study. Prim Care Companion CNS Disord. 2016 Sep 8;18(5). doi: 10.4088/PCC.15m01914.
Reference Type
BACKGROUND
Calkin CV, Ruzickova M, Uher R, Hajek T, Slaney CM, Garnham JS, O'Donovan MC, Alda M. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry. 2015 Jan;206(1):52-7. doi: 10.1192/bjp.bp.114.152850. Epub 2014 Oct 16.
Reference Type
BACKGROUND
Leopold K, Reif A, Haack S, Bauer M, Bury D, Loffler A, Kittel-Schneider S, Pfeiffer S, Sauer C, Schwarz P, Pfennig A. Type 2 diabetes and pre-diabetic abnormalities in patients with bipolar disorders. J Affect Disord. 2016 Jan 1;189:240-5. doi: 10.1016/j.jad.2015.09.041. Epub 2015 Sep 28.
Reference Type
BACKGROUND
Dargel AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. C-reactive protein alterations in bipolar disorder: a meta-analysis. J Clin Psychiatry. 2015 Feb;76(2):142-50. doi: 10.4088/JCP.14r09007.
Reference Type
BACKGROUND
Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik MS. Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment. Psychiatry Res. 2015 Aug 30;228(3):386-92. doi: 10.1016/j.psychres.2015.05.078. Epub 2015 Jun 27.
Reference Type
BACKGROUND
Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, Calabrese JR. PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs. 2014 Jun;28(6):571-81. doi: 10.1007/s40263-014-0158-2.
Reference Type
BACKGROUND
Mansur RB, Brietzke E, McIntyre RS. Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015 May;52:89-104. doi: 10.1016/j.neubiorev.2014.12.017. Epub 2015 Jan 8.
Reference Type
BACKGROUND
Bodnar M, Malla AK, Makowski C, Chakravarty MM, Joober R, Lepage M. The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study. BJPsych Open. 2016 Mar 9;2(2):139-146. doi: 10.1192/bjpo.bp.115.002444. eCollection 2016 Mar.
Reference Type
BACKGROUND
van Hees VT, Sabia S, Anderson KN, Denton SJ, Oliver J, Catt M, Abell JG, Kivimaki M, Trenell MI, Singh-Manoux A. A Novel, Open Access Method to Assess Sleep Duration Using a Wrist-Worn Accelerometer. PLoS One. 2015 Nov 16;10(11):e0142533. doi: 10.1371/journal.pone.0142533. eCollection 2015.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSS 5182913
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder
NCT07213492
RECRUITING
NA
Antidepressant Treatments and Cognitive Function of Bipolar Patients
NCT04564573
UNKNOWN
Brexpiprazole in Borderline Personality Disorder
NCT03418675
COMPLETED
PHASE2
A Study of JNJ-55308942 in the Treatment of Bipolar Depression
NCT05328297
COMPLETED
PHASE2
Cognitive Enhancement in Bipolar Disorder
NCT00597896
COMPLETED
PHASE4
Cannabidiol for Bipolar Depression (CBD-BD)
NCT05867849
RECRUITING
PHASE3
Natural History of Depression, Bipolar Disorder and Suicide Risk
NCT06462196
RECRUITING
Targeting Cognition in Bipolar Disorder With Pramipexole
NCT02397837
COMPLETED
PHASE4
Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression
NCT03567681
UNKNOWN
PHASE4
Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients
NCT02466685
COMPLETED
PHASE2
Depakote-ER for Depressive and Bipolar Depression
NCT00226343
COMPLETED
PHASE4
A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
NCT04100096
COMPLETED
PHASE2
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
NCT03692910
COMPLETED
PHASE2
Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
NCT00194116
COMPLETED
PHASE3
Clinical Evaluation of the Antidepressant Effect of the Use of Probiotics in Bipolar Disorder
NCT05762887
RECRUITING
NA
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
NCT04186403
COMPLETED
PHASE2/PHASE3
Does Bipolar Disease Program (BDP) Intervention Improve Long Term Manic and Depressive Symptoms.
NCT00007761
COMPLETED
PHASE3
Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression
NCT00475137
COMPLETED
PHASE2
Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression
NCT05177146
COMPLETED
NA
Depression And Bipolar Disorder
NCT00274677
COMPLETED
PHASE3
Treatment of Bipolar Depression With Pentoxifylline
NCT04417049
COMPLETED
EARLY_PHASE1
Deep Brain Stimulation for the Treatment of Refractory Bipolar Disorder
NCT01476527
COMPLETED
NA
Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression
NCT01403662
COMPLETED
PHASE3
Clinical Trial of Pramipexole in Bipolar Depression
NCT00025792
COMPLETED
PHASE2
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder
NCT06256367
ACTIVE_NOT_RECRUITING